CN110582511B - 抗N3pGlu淀粉状蛋白β肽抗体及其用途 - Google Patents

抗N3pGlu淀粉状蛋白β肽抗体及其用途 Download PDF

Info

Publication number
CN110582511B
CN110582511B CN201880025982.6A CN201880025982A CN110582511B CN 110582511 B CN110582511 B CN 110582511B CN 201880025982 A CN201880025982 A CN 201880025982A CN 110582511 B CN110582511 B CN 110582511B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880025982.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110582511A (zh
Inventor
R·B·德马托斯
J·卢
唐鹰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202310757235.4A priority Critical patent/CN117024583A/zh
Publication of CN110582511A publication Critical patent/CN110582511A/zh
Application granted granted Critical
Publication of CN110582511B publication Critical patent/CN110582511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880025982.6A 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途 Active CN110582511B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310757235.4A CN117024583A (zh) 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
US62/487,550 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310757235.4A Division CN117024583A (zh) 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途

Publications (2)

Publication Number Publication Date
CN110582511A CN110582511A (zh) 2019-12-17
CN110582511B true CN110582511B (zh) 2023-08-08

Family

ID=62111232

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880025982.6A Active CN110582511B (zh) 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途
CN202310757235.4A Pending CN117024583A (zh) 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310757235.4A Pending CN117024583A (zh) 2017-04-20 2018-04-16 抗N3pGlu淀粉状蛋白β肽抗体及其用途

Country Status (28)

Country Link
US (3) US10647759B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612559A1 (cg-RX-API-DMAC7.html)
JP (3) JP6900500B2 (cg-RX-API-DMAC7.html)
KR (2) KR102352670B1 (cg-RX-API-DMAC7.html)
CN (2) CN110582511B (cg-RX-API-DMAC7.html)
AR (1) AR111208A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018255221B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018810A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058482C (cg-RX-API-DMAC7.html)
CL (1) CL2019002922A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019011349A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190445A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000241A (cg-RX-API-DMAC7.html)
EA (1) EA201992163A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19075146A (cg-RX-API-DMAC7.html)
IL (1) IL269003B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20190247A1 (cg-RX-API-DMAC7.html)
MA (1) MA50144A (cg-RX-API-DMAC7.html)
MX (2) MX2019012445A (cg-RX-API-DMAC7.html)
NZ (1) NZ758066A (cg-RX-API-DMAC7.html)
PE (1) PE20200011A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502361A1 (cg-RX-API-DMAC7.html)
SA (1) SA519410311B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909022PA (cg-RX-API-DMAC7.html)
TW (2) TWI789644B (cg-RX-API-DMAC7.html)
UA (1) UA126806C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018194951A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201906159B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白-β之抗體及其用途
TWI789644B (zh) * 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
SG11202110504XA (en) 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
PE20231507A1 (es) * 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
MX2024004514A (es) * 2021-10-22 2024-05-07 Lilly Co Eli Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
CA3236560A1 (en) 2021-10-29 2023-05-04 Marcio Chedid Compounds and methods targeting interleukin-34
MX2024005144A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
US20260125460A1 (en) 2021-10-29 2026-05-07 Eli Lilly And Company Compounds and methods targeting interleukin-34
IL312380A (en) 2021-10-29 2024-06-01 Lilly Co Eli Compounds and methods targeting interleukin-34
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
CN117327168B (zh) * 2022-06-24 2026-06-19 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
CN120583962A (zh) * 2022-11-17 2025-09-02 伊莱利利公司 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
IL328051A (en) 2023-11-14 2026-06-01 Lilly Co Eli Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228316A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025255300A1 (en) * 2024-06-06 2025-12-11 Eli Lilly And Company FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026075947A1 (en) 2024-10-01 2026-04-09 Eli Lilly And Company Dosing regimens for early alzheimer's disease
WO2026122407A1 (en) * 2024-12-04 2026-06-11 Merck Sharp & Dohme Llc Amyloid beta binder, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426423A (zh) * 2000-02-24 2003-06-25 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
CN102617733A (zh) * 2005-04-29 2012-08-01 瑞纳神经科学公司 抗β-淀粉样肽抗体及其使用方法
CN103068848A (zh) * 2010-08-12 2013-04-24 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
CA2723995A1 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
KR101706789B1 (ko) 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
TWI789644B (zh) * 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426423A (zh) * 2000-02-24 2003-06-25 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
CN102617733A (zh) * 2005-04-29 2012-08-01 瑞纳神经科学公司 抗β-淀粉样肽抗体及其使用方法
CN103068848A (zh) * 2010-08-12 2013-04-24 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
CN105111308A (zh) * 2010-08-12 2015-12-02 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途

Also Published As

Publication number Publication date
CN117024583A (zh) 2023-11-10
US20210371509A1 (en) 2021-12-02
NZ758066A (en) 2022-10-28
WO2018194951A1 (en) 2018-10-25
CA3058482A1 (en) 2018-10-25
US11078261B2 (en) 2021-08-03
MX2022011817A (es) 2022-10-10
TWI789644B (zh) 2023-01-11
TWI705975B (zh) 2020-10-01
AU2018255221A1 (en) 2019-09-19
ECSP19075146A (es) 2019-10-31
ZA202007868B (en) 2023-06-28
US10647759B2 (en) 2020-05-12
JP6900500B2 (ja) 2021-07-07
AU2021203927A1 (en) 2021-07-08
ZA201906159B (en) 2026-03-25
DOP2019000241A (es) 2019-10-15
CO2019011349A2 (es) 2019-10-31
MA50144A (fr) 2020-07-29
KR102567295B1 (ko) 2023-08-16
TW202120541A (zh) 2021-06-01
CL2019002922A1 (es) 2020-03-13
KR20220011800A (ko) 2022-01-28
AU2018255221B2 (en) 2021-07-01
BR112019018810A2 (pt) 2020-05-05
KR102352670B1 (ko) 2022-01-19
KR20190129100A (ko) 2019-11-19
CN110582511A (zh) 2019-12-17
EP3612559A1 (en) 2020-02-26
JP2021151253A (ja) 2021-09-30
US20180305444A1 (en) 2018-10-25
SA519410311B1 (ar) 2022-03-20
PH12019502361A1 (en) 2020-07-13
UA126806C2 (uk) 2023-02-08
AU2021203927B2 (en) 2024-03-21
IL269003B1 (en) 2025-06-01
SG11201909022PA (en) 2019-11-28
JOP20190247A1 (ar) 2019-10-20
MX2019012445A (es) 2020-01-13
IL269003B2 (en) 2025-10-01
IL269003A (en) 2019-10-31
EA201992163A1 (ru) 2020-03-02
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
JP2023058623A (ja) 2023-04-25
AR111208A1 (es) 2019-06-12
CR20190445A (es) 2019-11-06
CA3058482C (en) 2023-05-09
JP2020510081A (ja) 2020-04-02
US20200262902A1 (en) 2020-08-20
TW201902924A (zh) 2019-01-16
PE20200011A1 (es) 2020-01-06

Similar Documents

Publication Publication Date Title
JP7532571B2 (ja) 抗N3pGluアミロイドベータペプチド抗体およびその使用
US9944696B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
CN107847595A (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
EA048806B1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение
BR122024022779A2 (pt) Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab
BR112018011308B1 (pt) Anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant